MA34556B1 - Triazoles fusionnés pour le traitement ou la prophylaxie du trouble cognitif léger - Google Patents

Triazoles fusionnés pour le traitement ou la prophylaxie du trouble cognitif léger

Info

Publication number
MA34556B1
MA34556B1 MA35785A MA35785A MA34556B1 MA 34556 B1 MA34556 B1 MA 34556B1 MA 35785 A MA35785 A MA 35785A MA 35785 A MA35785 A MA 35785A MA 34556 B1 MA34556 B1 MA 34556B1
Authority
MA
Morocco
Prior art keywords
fusioned
triazoles
prophylaxis
treatment
cognitive disorders
Prior art date
Application number
MA35785A
Other languages
English (en)
Inventor
Tatsuki Koike
Minoru Nakamura
Yoshihide Tomata
Takafumi Takai
Yasutaka Hoashi
Yuichi Kajita
Tetsuya Tsukamoto
Makoto Kamata
Original Assignee
Takeda Pharmaceutcal Company Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45094181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34556(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutcal Company Ltd filed Critical Takeda Pharmaceutcal Company Ltd
Publication of MA34556B1 publication Critical patent/MA34556B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'invention concerne un dérivé hétérocyclique ayant une meilleure activité inhibitrice de la production d'amyloïde ß et/ou une meilleure activité modulatrice de la ³-secrétase, et son utilisation. L'invention concerne également un composé représenté par la formule (I) dans laquelle chaque symbole est défini dans la description, ou un sel de ce composé.
MA35785A 2010-09-02 2011-09-01 Triazoles fusionnés pour le traitement ou la prophylaxie du trouble cognitif léger MA34556B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2010197064 2010-09-02
JP2011143548 2011-06-28
PCT/JP2011/070419 WO2012029991A1 (fr) 2010-09-02 2011-09-01 Triazoles fusionnés pour le traitement ou la prophylaxie du trouble cognitif léger

Publications (1)

Publication Number Publication Date
MA34556B1 true MA34556B1 (fr) 2013-09-02

Family

ID=45094181

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35785A MA34556B1 (fr) 2010-09-02 2011-09-01 Triazoles fusionnés pour le traitement ou la prophylaxie du trouble cognitif léger

Country Status (21)

Country Link
US (3) US8822699B2 (fr)
EP (1) EP2611805A1 (fr)
JP (1) JP5871909B2 (fr)
KR (1) KR20130139895A (fr)
CN (1) CN103249733A (fr)
AR (1) AR082865A1 (fr)
AU (1) AU2011296887A1 (fr)
BR (1) BR112013004746A2 (fr)
CA (1) CA2809779A1 (fr)
CL (1) CL2013000575A1 (fr)
DO (1) DOP2013000051A (fr)
EA (1) EA201390333A1 (fr)
EC (1) ECSP13012535A (fr)
MA (1) MA34556B1 (fr)
MX (1) MX2013002511A (fr)
PE (1) PE20131305A1 (fr)
SG (1) SG187917A1 (fr)
TW (1) TW201213327A (fr)
UY (1) UY33586A (fr)
WO (1) WO2012029991A1 (fr)
ZA (1) ZA201301929B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120142672A1 (en) * 2009-07-13 2012-06-07 Tatsuki Koike Heterocyclic compound and use thereof
KR20130139895A (ko) * 2010-09-02 2013-12-23 다케다 야쿠힌 고교 가부시키가이샤 경도인지 장애의 치료 또는 예방용 융합 트리아졸
EP2687528A1 (fr) * 2012-07-17 2014-01-22 Ares Trading S.A. Dérivés de triazole fusionnés comme modulateurs de gamma-sécrétase
RU2563254C2 (ru) * 2013-07-08 2015-09-20 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Способ получения производных 7-(гетеро)арил-4,5,6,7-тетрагидро[1,2,3]триазоло[1,5-a]пиридина
PL3294743T3 (pl) * 2015-05-12 2020-03-31 Fmc Corporation Podstawione arylem związki bicykliczne jako środki chwastobójcze
US20210079182A1 (en) * 2019-09-12 2021-03-18 Dupont Electronics, Inc. Polyimide films and electronic devices
MX2024005884A (es) * 2021-12-17 2024-05-29 Athira Pharma Inc Usos de compuestos biciclicos para el tratamiento de enfermedades.

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6525044B2 (en) 2000-02-17 2003-02-25 Bristol-Myers Squibb Company Succinoylamino carbocycles and heterocycles as inhibitors of a-β protein production
CN102584813B (zh) 2003-05-14 2016-07-06 Ngc药物公司 化合物及其在调节淀粉样蛋白β中的用途
AU2004282201A1 (en) * 2003-10-15 2005-04-28 Targacept, Inc. Azabicycyclic compounds for relieving pain and treating central nervous system disorders
KR101128065B1 (ko) 2004-05-26 2012-04-12 에자이 알앤드디 매니지먼트 가부시키가이샤 신나미드 화합물
US7923563B2 (en) 2004-10-26 2011-04-12 Eisai R&D Management Co., Ltd. Amorphous object of cinnamide compound
JP2009523170A (ja) 2006-01-11 2009-06-18 メルク エンド カムパニー インコーポレーテッド 縮合トリアゾールタキキニン受容体アンダニスト
TWI378091B (en) 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
EP1992618B1 (fr) 2006-03-09 2012-01-18 Eisai R&D Management Co., Ltd. Dérivé polycyclique de cinnamide
TW200808800A (en) 2006-05-05 2008-02-16 Astrazeneca Ab MGluR5 modulators V
US8143394B2 (en) 2006-12-26 2012-03-27 Gilead Sciences, Inc. Pyrido(3,2-d)pyrimidines useful for treating viral infections
WO2008078725A1 (fr) 2006-12-26 2008-07-03 Daiichi Sankyo Company, Limited Dérivé de thiazépine
CA2677296A1 (fr) 2007-02-08 2008-08-14 Merck & Co., Inc. Agents therapeutiques
US8450343B2 (en) 2007-12-06 2013-05-28 Xianhai Huang Gamma secretase modulators
TW201030002A (en) 2009-01-16 2010-08-16 Bristol Myers Squibb Co Bicyclic compounds for the reduction of beta-amyloid production
JP2010197064A (ja) 2009-02-23 2010-09-09 Chugoku Electric Power Co Inc:The 直下位置測定装置
MX2011008501A (es) 2009-02-26 2011-09-01 Eisai R&D Man Co Ltd Compuestos heterociclicos fusionados que contienen nitrogeno y su uso como inhibidores de la produccion de beta-amiloide.
JP2012051806A (ja) * 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd イミダゾリルピラジン誘導体
JP2012051807A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd アリールイミダゾール化合物
WO2011002067A1 (fr) 2009-07-02 2011-01-06 武田薬品工業株式会社 Composé hétérocyclique et son utilisation
US20120142672A1 (en) 2009-07-13 2012-06-07 Tatsuki Koike Heterocyclic compound and use thereof
US8946266B2 (en) 2009-07-15 2015-02-03 Janssen Pharmaceuticals, Inc. Substituted triazole and imidazole derivatives as gamma secretase modulators
TWI468402B (zh) 2009-07-31 2015-01-11 必治妥美雅史谷比公司 降低β－類澱粉生成之化合物
US8637525B2 (en) 2009-07-31 2014-01-28 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
WO2011016559A1 (fr) 2009-08-07 2011-02-10 武田薬品工業株式会社 Composé hétérocyclique et son utilisation
JP2011143548A (ja) 2010-01-12 2011-07-28 Panasonic Corp スクリーン印刷機及びスクリーン印刷方法
CN102906083A (zh) 2010-01-15 2013-01-30 杨森制药公司 作为γ分泌酶调节剂的新的取代的三唑衍生物
KR20130139895A (ko) * 2010-09-02 2013-12-23 다케다 야쿠힌 고교 가부시키가이샤 경도인지 장애의 치료 또는 예방용 융합 트리아졸

Also Published As

Publication number Publication date
US20120059030A1 (en) 2012-03-08
AU2011296887A1 (en) 2013-04-11
EP2611805A1 (fr) 2013-07-10
BR112013004746A2 (pt) 2016-06-07
KR20130139895A (ko) 2013-12-23
PE20131305A1 (es) 2013-10-31
US8901309B2 (en) 2014-12-02
ECSP13012535A (es) 2013-06-28
JP2013536798A (ja) 2013-09-26
TW201213327A (en) 2012-04-01
AR082865A1 (es) 2013-01-16
SG187917A1 (en) 2013-04-30
CN103249733A (zh) 2013-08-14
WO2012029991A1 (fr) 2012-03-08
MX2013002511A (es) 2013-07-29
US20130178497A1 (en) 2013-07-11
ZA201301929B (en) 2013-11-27
US20140350260A1 (en) 2014-11-27
JP5871909B2 (ja) 2016-03-01
DOP2013000051A (es) 2013-04-30
US8822699B2 (en) 2014-09-02
UY33586A (es) 2012-03-30
CL2013000575A1 (es) 2013-08-23
EA201390333A1 (ru) 2013-08-30
CA2809779A1 (fr) 2012-03-08

Similar Documents

Publication Publication Date Title
MA34556B1 (fr) Triazoles fusionnés pour le traitement ou la prophylaxie du trouble cognitif léger
EA201491283A1 (ru) Ингибитор регулирующей апоптотические сигналы киназы
MA35623B1 (fr) Composés de 1-arylcarbonyl-4-oxypipéridine utiles pour le traitement de maladies neurodégénératives
MA38390A1 (fr) Composés tétrahydropyrrolothiazines
MA34713B1 (fr) Compose bicyclique
EA201791070A1 (ru) Способы получения ингибиторов ask1
EA201690153A1 (ru) Замещенные бензофуранильные и бензоксазолильные соединения и их применения
MA35193B1 (fr) Halogeno-alkyl-1,3 oxazines en tant qu'inhibiteurs de bace1 et/ou bace2
MA35364B1 (fr) Dérivés hétérocycliques bicycliques pour le traitement d'une hypertension artérielle pulmonaire
EA201591753A1 (ru) 3-пиримидин-4-илоксазолидин-2-оны в качестве ингибиторов мутантного idh
MA35191B1 (fr) Spiro-[1,3]-oxazines et spiro-[1,4]-oxazepines en tant qu'inhibiteurs de baec1 et/ou bace2
EA201690094A1 (ru) Ингибиторы syk
EA201891703A1 (ru) Соединения бензопиразола и их аналоги
MA32911B1 (fr) Derives de benzothiazole convenant comme agents agents anticancereux
MA38556A1 (fr) Inhibiteurs de bace1
EA201591614A1 (ru) Соединения 1,3-оксазин-2-амина, конденсированные с перфторированным циклопропилом, в качестве ингибиторов бета-секретазы и способы их применения
EA201690458A1 (ru) Фуро- и тиенопиридинкарбоксамиды, используемые в качестве ингибиторов pim-киназы
GEP20166554B (en) Nitrogenated heterocyclic compound
EA201500574A1 (ru) Новые инданилоксидигидробензофуранилуксусные кислоты
TN2015000347A1 (fr) Azabenzimidazoles servant d'inhibiteurs d'isoenzymes pde4 pour le traitement de troubles du snc et d'autres troubles
EA201301040A1 (ru) Гетероциклическое соединение и его применение
MA33559B1 (fr) Composes bicycliques 5,6- heteroaryle contenant l'uree comme inhibiteurs de kinase.
EA201790206A1 (ru) Новые 2,5-замещенные пиримидины в качестве ингибиторов pde4
MA44021A (fr) Composés antitumoraux
MA37691B1 (fr) 5-amino[1,4]thiazines comme inhibiteurs de bace1